[1] 中国中西医结合学会检验医学专业委员会.非传统血脂指标与动脉粥样硬化性心血管疾病风险管理中国专家共识[J].中华预防医学杂志,2022,56(4):405-421. [2] White HD, Stewart RAH, Dalby AJ,et al.In patients with stable coronary heart disease,low density lipoprotein cholesterol levels<70 mg/dL and glycosylated hemoglobin A1c<7% are associated with lower major cardiovascular events[J].Am Heart J,2020,225:97-107. [3] Mach F, Baigent C, Catapano AL,et al.2019 ESC/EAS Guidelines for themanagement of dyslipidaemias:lipid modification to reduce cardiovascular risk[J].Eur Heart J,2020,41(5):111-188. [4] Bytyci I,Penson PE,Mikhailidis DP,et al.Prevalence of statin intolerance:a meta analysis[J].Eur Heart J,2022,43(34):3213-3223. [5] 马蕊,张莉莉,韩冰,等.前蛋白转化酶枯草溶菌素9抑制剂对他汀类药物不耐受急性冠脉综合征患者血脂影响[J].临床军医杂志,2020,48(5):581-582,585. [6] Mao P, Liu X, Weng Y,et al.Clinical efficacy of aspirin combination treatment in the treatment of coronary heart disease and its effect on inflammatory factors:a systematic review and meta analysis[J].Ann Palliat Med,2021,10(8):8858-8868. [7] Luquero A,Badimon L,Borrell-pages M.PCSK9 functions in atherosclerosis are not limited to plasmatic ldl cholesterol regulation[J].Front Cardiovasc Med,2021,8:639727. [8] 王瑞杰,王亮,徐丹,等.PCSK9抑制剂对冠心病患者血脂及炎症因子的影响[J].中国临床药理学与治疗学,2022,27(4):409-417. [9] Xiang QY, Tian F, Lin QZ,et al.Comparison of remnant cholesterol levels estimated by calculated and measured LDL-C levels in Chinese patients with coronary heart disease[J].Clin Chim Acta,2020,500:75-80. [10] 中华医学会心血管病分会动脉粥样硬化与冠心病学组,中华心血管病杂志编辑委员会.超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识[J].中华心血管病杂志,2020,48(4):280-286. [11] Roth EM, Kastelein JJP, Cannon CP,,et al.Pharmacodynamic relationship between PCSK9,alirocumab,and LDL-C lowering in the ODYSSEY CHOLCE I trial[J].J Clin Lipidol,2020,14(5):707-719. [12] 王均强,董少华,阿丽娜,等.依洛尤单抗联合他汀类药物治疗急性冠脉综合征患者高血脂的疗效与安全性评价[J].解放军医学院学报,2022,43(1):6-10. [13] Ridker PM, MacFadyen JG, Thuren T,et al.Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab:further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis[J].Eur Heart J,2020,41(23):2153-2163. [14] Gager GM, Biesinger B, Hofer F,et al.Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome[J].VasculPharmacol,2020,135:106806. [15] Rai H, Colleran R, Cassese S,et al.Association of interleukin 6-174 G/C polymorphism with coronary artery disease and circulating IL-6 levels:a systematic review and meta-analysis[J].Inflamm Res, 2021, 70(10-12):1075-1087. [16] Xu HX, Cui Y, Liu XW, et al.miR-1290 promotes IL-8-mediated vascular endothelial cell adhesion by targeting GSK-3β[J]. Mol Biol Rep, 2022, 49(3):1871-1882. [17] 王锐, 吴永刚, 聂鹏飞, 等.参七脉心通胶囊对经皮冠脉介入术后患者支架内再狭窄及炎症因子的影响[J]. 中国当代医药, 2024, 31(10):66-70. [18] Barcelos ALV, de Oliveira EA, Haute GV,et al.Association of IL-10 to coronary disease severity in patients with metabolic syndrome[J].Clin Chim Acta,2019,495:394-398. [19] 杨鸣宇,李康荣,何航宇.IL-10及相关促炎因子与冠心病伴代谢综合征患者冠状动脉病变程度的关系[J].广东医学,2021,42(8):988-991. [20] Haybar H, Bandar B, Torfi E, et al.Cytokines and their role in cardiovascular diseases[J]. Cytokine. 2023, 169(156261):1-10. [21] Zhong DX, Zhang Y, Jin Q,et al.Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension:insights from inflammatory cytokines[J].PulmCir,2021,11(4):20458940211051292. [22] 张晓文,王祎,张婵,等.PCSK9基因干扰对高脂诱导的大鼠非酒精性脂肪性肝病合并动脉粥样硬化的影响[J].上海交通大学学报(医学版),2022,42(2):150-157. [23] Punch E, Klein J, Diaba-Nuhoho P,et al.Effects of PCSK9 targeting:Alleviating Oxidation,inflammation,and atherosclerosis[J].J Am Heart Assoc,2022,11(3):e23328. |